The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD-1) has
revolutionized the landscape of multiple human cancer types, including head and neck …

Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double …

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Gemcitabine plus cisplatin (GP) chemotherapy is the standard of care for nasopharyngeal
carcinoma (NPC). However, the mechanisms underpinning its clinical activity are unclear …

Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with extremely skewed
ethnic and geographic distributions. Increasing evidence indicates that targeting the tumor …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and …

Epstein-Barr virus (EBV), a gamma-1 herpesvirus, is carried as a life-long asymptomatic
infection by the great majority of individuals in all human populations. Yet this seemingly …